3,003 Shares in DaVita Inc. $DVA Bought by Watershed Asset Management L.L.C.

Watershed Asset Management L.L.C. acquired a new stake in shares of DaVita Inc. (NYSE:DVA) during the first quarter, Holdings Channel reports. The fund acquired 3,003 shares of the company’s stock, valued at approximately $462,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Gen Wealth Partners Inc raised its stake in shares of DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after purchasing an additional 80 shares in the last quarter. NewEdge Advisors LLC grew its stake in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares in the last quarter. Orion Porfolio Solutions LLC increased its holdings in DaVita by 4.4% in the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after buying an additional 99 shares during the last quarter. Root Financial Partners LLC increased its holdings in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after buying an additional 105 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in DaVita by 3.9% during the first quarter. Bessemer Group Inc. now owns 2,962 shares of the company’s stock valued at $456,000 after buying an additional 110 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.90% of the company’s stock.

DaVita Stock Up 1.2%

Shares of NYSE DVA opened at $236.93 on Friday. The firm’s 50-day moving average price is $209.94 and its two-hundred day moving average price is $164.49. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $239.64. The stock has a market capitalization of $15.21 billion, a P/E ratio of 21.98, a P/E/G ratio of 0.77 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita Inc. will post 15.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on DVA. UBS Group increased their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and upped their price target for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, TD Cowen boosted their target price on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $216.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.